Search Within

Wassim Abida

Formats
  1. Meeting Abstract (75)
  2. Journal Article (69)
  3. Editorial (4)
  4. Research Letter (2)
  5. Review (2)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (154)
  2. Genitourinary Oncology Service (154)
  3. Solid Tumor Oncology Division (154)
  4. GSK Faculty (71)
  5. Human Oncology and Pathogenesis Program (67)
  6. Sloan Kettering Institute Postdocs (57)

More Groups

People
  1. Howard Scher (68)
  2. Michael Morris (38)
  3. David Solit (36)
  4. Nikolaus Schultz (32)
  5. Anuradha Gopalan (31)
  6. Dana Rathkopf (31)

More People

Years
  1. 2025 (4)
  2. 2024 (10)
  3. 2023 (14)
  4. 2022 (15)
  5. 2021 (19)
  6. 2020 (27)

More Years

Publications
  1. Journal of Clinical Oncology (40)
  2. Clinical Cancer Research (15)
  3. Annals of Oncology (13)
  4. Cancer Research (13)
  5. European Urology (8)
  6. JCO Precision Oncology (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (44)
  2. American Association for Cancer Research (31)
  3. Nature Publishing Group (15)
  4. Oxford University Press (13)
  5. Elsevier Science, Inc. (10)
  6. Nature Research (5)

More Publishers

Results (154)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Microsatellite instability in prostate cancer and response to immune checkpoint blockade
    Meeting Abstract

    Abida, W.; Cheng, M. L.; Armenia, J.; Middha, S.; Autio, K. A.; Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Carbone, E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers
    Meeting Abstract

    Krebs, M. G.; Lopez, J.; El-Khoueiry, A.; Bang, Y. J.; Postel-Vinay, S.; Abida, W.; Carter, L.; Xu, W.; Im, S. A.; Pierce, A.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Evolving intersection between inherited cancer genetics and therapeutic clinical trials in prostate cancer: A white paper from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium
    Journal Article

    Carlo, M. I.; Giri, V. N.; Paller, C. J.; Abida, W.; Alumkal, J. J.; Beer, T. M.; Beltran, H.; George, D. J.; Heath, E. I.; Higano, C. S.; more...
    JCO Precision Oncology (2018)

    Fulltext@MSK | Save
  • Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Chowdhury, S.; McDermott, R.; Piulats, J. M.; Shapiro, J. D.; Mejlholm, I.; Morris, D.; Ostler, P.; Hussain, A.; Dumbadze, I.; Goldfischer, E. R.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations
    Meeting Abstract

    Abida, W.; Bryce, A. H.; Vogelzang, N. J.; Amato, R. J.; Percent, I.; Shapiro, J. D.; McDermott, R.; Hussain, A.; Patnaik, A.; Petrylak, D.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma
    Meeting Abstract

    Krebs, M.; Lopez, J.; El-Khoueiry, A.; Bang, Y. J.; Postel-Vinay, S.; Abidah, W.; Im, S. A.; Khoja, L. T.; Standifer, N.; Jones, G. N.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer
    Meeting Abstract

    Vaishampayan, U. N.; Narayan, V.; Wise, D.; Lang, J. M.; Lowentritt, B. H.; Mellado, B.; Carles, J.; Saez, M. I.; Abida, W.; Taplin, M. E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician's choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
    Meeting Abstract

    Ryan, C. J.; Abida, W.; Bryce, A. H.; Balar, A. V.; Dumbadze, I.; Given, R. W.; Morris, D.; Petrylak, D. P.; Redfern, C. H.; Scher, H. I.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • c15-153: Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naive prostate cancer that retains RB expression
    Meeting Abstract

    Kelly, W. K.; Godwin, J. L.; Hoffman-Censits, J. H.; Knudsen, K. E.; De Leeuw, R.; Leiby, B. E.; Southwell, T.; Hubert, C.; Smith, D. C.; Chatta, G. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
    Meeting Abstract

    Abida, W.; Bryce, A. H.; Balar, A. V.; Chatta, G. S.; Dawson, N. A.; Guancial, E. A.; Hussain, A.; Jha, G. G.; Lipsitz, D. U.; Patnaik, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save